Catalyst Capital Advisors LLC maintained its stake in Sanofi (NYSE:SNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,400 shares of the company’s stock at the end of the second quarter. Catalyst Capital Advisors LLC’s holdings in Sanofi were worth $2,175,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Guggenheim Capital LLC boosted its stake in Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares during the last quarter. Goodwin Daniel L purchased a new stake in Sanofi during the second quarter valued at approximately $239,000. Wellington Management Group LLP purchased a new stake in Sanofi during the first quarter valued at approximately $2,252,000. Cullinan Associates Inc. boosted its stake in Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in Sanofi by 8.6% in the first quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after buying an additional 25,009 shares during the last quarter. Hedge funds and other institutional investors own 9.96% of the company’s stock.

Shares of Sanofi (NYSE SNY) opened at 47.55 on Friday. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The company has a 50-day moving average price of $47.99 and a 200-day moving average price of $46.11. The company has a market cap of $119.42 billion, a PE ratio of 11.23 and a beta of 0.88.

Sanofi (NYSE:SNY) last issued its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm’s revenue was down 2.3% on a year-over-year basis. Equities research analysts expect that Sanofi will post $3.26 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Catalyst Capital Advisors LLC Maintains Position in Sanofi (SNY)” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/13/catalyst-capital-advisors-llc-maintains-position-in-sanofi-sny.html.

SNY has been the topic of several research reports. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Thursday, April 20th. Cowen and Company restated a “market perform” rating and issued a $52.00 target price (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. Finally, Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. Sanofi currently has a consensus rating of “Hold” and a consensus target price of $63.75.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.